

BEST AVAILABLE COPY

RECEIVED
CENTRAL FAX CENTER

APR 05 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300 at MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 5, 2006

Signature: 

(Danielle L. Herritt)

Docket No.: NBI-193
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Xianqi Kong *et al.*

Application No.: 10/763953

Confirmation No.: 5062

Filed: January 23, 2004

Art Unit: 1614

For: AMIDINE DERIVATIVES FOR TREATING
AMYLOIDOSIS

Examiner: J. M. Nolan

RESPONSE TO RESTRICTION REQUIREMENTMS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the restriction requirement set forth in the Office Action mailed October 14, 2005.

The Examiner has required restriction between the following inventions in the above-identified application:

- I. Claims 8 and 23-25, drawn to compounds and compositions of the formulas I classified in multiple subclasses of classes 564, 548, 514.
- II. Claims 1-7, drawn to methods of using the compounds, classified in multiple subclasses of class 514.


The Examiner has also required an election of a single compound within either Group.

Accordingly, Applicants hereby elect Group I, Claims 8, and 23-25 for continued examination. Applicants also elect the following single compound for continued examination:

BEST AVAILABLE COPY

Application No.: 10/763953

Docket No.: NBI-193



4,4'-(pentamethylenediamidino)di(*p*-methoxybenzene), hydrochloride salt.

It is Applicants understanding that examination will proceed on the elected compound and the entire scope of the invention encompassing the elected species. Furthermore, Applicants reserve the right to file divisional applications on the remaining subject matter, if so desired.

Lastly, Applicants would like to note that in accordance with MPEP 821.04 and *In re Ochiai*, 71 F.3d 1565, 37 USPQ 1127 (Fed. Cir. 1995), rejoinder of product claims with process claims commensurate in scope with the allowed product will occur following a finding that the product claims are allowable.

An appropriate Request for Extension of Time is filed concurrently herewith. Please charge any additional fees or credit any overpayments to our Deposit Account No. 12-0080, under Order No. NBI-193 from which the undersigned is authorized to draw.

Dated: April 5, 2006

Respectfully submitted,

By 

Danielle L. Herritt

Registration No.: 43,670

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant